

# Respiratory Multi Well System r-gene®

Influenza A/B r-gene® - ref.: 71-040 • RSV/hMPV r-gene® - ref.: 71-041 Rhino&EV/Cc r-gene® - ref.: 71-042 • AdV/hBoV r-gene® - ref.: 71-043 Chla/Myco pneumo r-gene® - ref.: 71-044 · HCoV/HPIV r-gene® - ref.: 71-045 Legio pneumo/Cc r-gene® - ref.: 71-046





## EXTRACTION

- IN EXTRACTION ROOM -

Respiratory samples\*: nasal washes, nasal swabs,

\* Refer to the technical datasheet of each product to check which respiratory samples are validated

#### Perform extraction as indicated below:

INSTRUMENTS	КІТ	SAMPLE VOLUME	SAMPLE TYPE	PROTOCOL	ELUTION VOLUME
NucliSENS® easyMAG® (1)	NucliSENS <sup>®</sup> easyMAG <sup>®</sup> Reagents	200 μL	Respiratory samples	Specific B + 50 µL de silice	50 μL
(bioMérieux)		400 μL			100 μL
MagNAPure Compact (2) (Roche Diagnostics)	MagNAPure Compact Nucleic acid Isolation Kit I	200 μL		Total_NA_plasma_	50 μL
(Hoche Diagnostics)		400 μL		_100_400	100 μL
QIAsymphony SP (3) (Qiagen)				Pathogen Complex 200	85 μL

(1) A proteinase K pre-treatment prior to extraction on the NucliSENS<sup>®</sup> easyMAG<sup>®</sup> instrument may be required if a sample is considered to be too mucous. In this case, add 10  $\mu$ L for 200  $\mu$ L and 20  $\mu$ L for 400  $\mu$ L of proteinase K at 20 mg/mL and leave to incubate for 15 minutes at 56°C.

(2) For Legio pneumo/Cc r-gene<sup>®</sup>, a pre-treatment prior to extraction on the MagNAPure Compact instrument may be required if a sample is considered to be too mucous. In this case, only use 200  $\mu$ L of sample, add 20  $\mu$ L of proteinase K at 20 mg/mL (proteinase K recombinant PCR grade Roche Diagnostics, ref.: 03 115 887 001) and 180  $\mu$ L of MagNAPure Bacteria Lysis Buffer (Roche Diagnostics ref.: 04 659 180 001). Incubate for 30 minutes at 63°C. Extract the totality, i.e. 400  $\mu$ L (sample volume to be specified on the instrument), the elution is performed in 50  $\mu$ L.

(3) Not CE-marked with Legio pneumo/Cc r-gene®

#### **ANCILLARY REAGENTS:**

• CELL Control r-gene® - ref.: 71-106 kit to check the presence of cells in the sample. • DICO Extra r-gene® - ref.: 71-101 •RICO Extra r-gene® - ref.: 71-105

GLOSSARY:

PC4X Positive Control W0

Negative Extraction + Amplification Control R4X **Amplification Premix** 

CT Crossing Threshold RT Reverse Transcriptase

S Sample

# **AMPLIFICATION**

#### - IN AMPLIFICATION ROOM -

Applied Biosystems LightCycler 480 7500 Fast,7500 Fast Dx, 530 & 560

Stratagene Mx3005P Agilent Mx3005P Versant kPCR AD FAM & HFX

Dx Real-Time System (Bio-Rad)

Rotor-Gene Q GREEN & YELLOW

Refer to the technical datasheet of each product to check which amplification platforms are validated

#### AMPLIFICATION PROGRAM

	STEPS		TIME	TEMPERATURE	CYCLES FLUORESCEN ACQUISITION	
	Reverse Transcription		5 min.	50°C	1	-
	Taq Polymerase Activation		15 min.	95°C	1	-
		Denaturation	10 sec.	95°C		-
	Amplification	Annealing	40 sec.	60°C	45	530 + 560 nm
		Elongation	25 sec.	72°C		-

Note 1: the temperature variations are parametered by default, which means at 100% or at their maxima. Note 2: on LightCycler 480, only "System II" is compatible with the use of the kits. The "System II" features an automatically activated colour compensation inits software

Note 3: on Applied Biosystems 7500 Fast, 7500 Fast Dx, ViiA7, select ROX as PASSIVE REFERENCE when

Note 4: on Applied Biosystems StepOne only, select NONE as PASSIVE REFERENCE when programming. Note 5: on Rotor-Gene Q, calibrate the signal by clicking on GAIN OPTIMISATION.

Note 6: on Stratagene Mx3005P or Agilent Mx3005P or Versant kPCR Molecular System AD, select NONE in REFERENCE DYE when programming.

#### **AMPLIFICATION PREPARATION**

#### Preparation of the premix

Plan "n" wells for amplification taking into account:

number of samples to be amplified; number of Positive Control (PC4X);

number of Negative Extraction + Amplification Control (W0):

(ref.: TCS0803).

#### Step to be added for RNA premix only

- Pipet 15 µL x (n+1) AmplificationPremix (R4X);
- Dilute 1 volume RT (1  $\mu$ L) into 9 volumes H<sub>2</sub>O (9  $\mu$ L);
- Add 0.15 µL x (n+1) diluted Reverse Transcriptase.

### Preparation of PCR assay

For RNA detection: Distribute 15  $\mu$ L of the previous premix (R4X + diluted RT) in the amplification wells:

For DNA detection: Distribute 15 µL of amplification premix (R4X) in the amplification wells.

- Add 10 µL of extracted sample, positive control (PC4X), extracted W0.
- Centrifuge for 15 sec, if applicable.
- Place the plate in the instrument and run the program described above according to the protocol of the instrument used.

### RESULTS

#### **TEST VALIDATION CONDITIONS**

W0 read at 530 nm and 560 nm: NO SIGNAL.

PC4X read at 530 nm and 560 nm: CT < 32 CYCLES.

#### INTERPRETATION OF THE RESULTS

RESULTS		Target A - 530 nm			
		CT calculated < 40 cycles	No CT calculated or CT ≥ 40 cycles		
- 560 nm	CT calculated < 40 cycles	Target A & B* +	Target A - Target B + if cellular control validated		
Target B	No CT calculated or CT ≥ 40 cycles	Target A + Target B - if cellular control validated	Target A & B - if cellular control validated		

\*For Applied Biosystems StepOne and Rotor-Gene Q apparatus, a crosstalk from 530 nm into 560 nm may be observed.

Note: The evaluation of the efficacy of the extraction and the detection of potential inhibitors is possible using the DICO Extra r-gene® ref.: 71-101 / RICO Extra r-gene® ref.: 71-105 reagents.

Note: Certain batches of transport media used for routing and storage of respiratory samples may contain traces of genomic DNA likely to give a false positive result beyond 35 cycles\*. For the same reasons, the use of inhibition controls IC1 (RICO Extra r-gene®) or IC2 (DICO Extra r-gene®) Note for Dx Real-Time System, use transparent plates (ref.: HSP9601) with optical caps in combination with this cellular control may also engender weakly positive signals beyond 35 cycles. In both cases, any sample with a CT value for the cellular control target greater than 35 cycles is considered to be a sample with an insufficient number of cells to be interpreted as valid. This sample must be retested or taken again.

> \*at 560 nm (cell control channel) for kits containing cellular control (Rhino&EV/Cc r-gene® ref.: 71-042 and Legio pneumo/Cc r-gene® ref.: 71-046)

This outlined procedure does not replace the original protocol See Package Insert

Reference 71-040 - 71-040CE v2 Reference 71-044 - 71-044CE v2 Reference 71-041 - 71-041CE v2 Reference 71-045 - 71-045CE v2 Reference 71-042 - 71-042CE v3 Reference 71-046 - 20682 - A. Reference 71-043 - 71-043CE v2




# Respiratory Multi Well System r-gene®


Influenza A/B r-gene® - ref.: 71-040 • RSV/hMPV r-gene® - ref.: 71-041
Rhino&EV/Cc r-gene® - ref.: 71-042 • AdV/hBoV r-gene® - ref.: 71-043
Chla/Myco pneumo r-gene® - ref.: 71-044 • HCoV/HPIV r-gene® - ref.: 71-045
Legio pneumo/Cc r-gene® - ref.: 71-046





# Principle for Respiratory Multi Well System r-gene® detection





Reference 71-043 - 71-043CE v2



BIOMERIEUX, the blue logo, ARGENE, R-gene, r-gene, easyMAG and NucliSENS are used, pending and/or registered trademarks belonging to bioMérieux, or one of its subsidiaries, or one of its companies.

Any other name or trademark is the property of its respective owner.

bioMérieux SA
Chemin de l'Orme
69280 Marcy-l'Étoile - France

RCS LYON 673 620 399 Tel.: 33 (0)4 78 87 20 00 Fax: 33 (0)4 78 87 20 90 www.biomerieux.com



This outlined procedure does not replace the original protocol See Package Insert

Reference 71-040 - 71-040CE v2 Reference 71-044 - 71-044CE v2
Reference 71-041 - 71-041CE v2 Reference 71-045 - 71-045CE v2
Reference 71-042 - 71-042CE v3 Reference 71-046 - 20682 - A.